Search Medical Condition
Please enter condition
Please choose location from dropdown

Bruay-la-Buissiere, France Clinical Trials

A listing of Bruay-la-Buissiere, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (25) clinical trials

End Of Life in the Critically Ill patiEnt

More than 20% of deaths occur in hospital after a stay in intensive care units; up to half of them happens as result of a treatment limitation. Ensuring end-of-life quality is important, not only because is a moral duty of all caregivers, but also to prevent negative effects in close ...

Phase N/A

1.92 miles

Learn More »

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

PHASE I: 3 cycles of Brentuximab Vedotin ICE every 3 weeks and one cycle of Brentuximab Vedotin alone at the doses described below. Cohorts of between three and six evaluable patients will be recruited at each dose level. Dose escalation rules: Treat 3 patients at level K If 0 patients ...

Phase

2.52 miles

Learn More »

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative ...

Phase

2.52 miles

Learn More »

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

The primary purpose of Parts A and B of this study is to determine a recommended dose level of prexasertib (an inhibitor of checkpoint kinase 1[Chk-1]) in combination with cisplatin and radiation therapy (Part A) or cetuximab and radiation therapy (Part B) in participants with locally advanced head and neck ...

Phase

2.52 miles

Learn More »

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

Eligible patients can be randomized via the TENALEA web site process that insure centralization of the randomization. Randomization will be performed according a 1:1:1:1 ratio. The randomization will be stratified (by minimization) according to the number of risk factors (2 vs.3), disease extent (pN- vs. pN+ vs. pNx) and the ...

Phase

2.52 miles

Learn More »

Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity

Chronic iron overload are responsible for morbidity and mortality. There are many causes, genetic and acquired. Hepcidin deficiency related to genetic desease is one of them. This study concerns specifically this cause, and seeks to characterize these iron overloads on clinical, biological, genetic and functional point of view. A significant ...

Phase N/A

2.52 miles

Learn More »

Tysabri Observational Program

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 10 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use, and the impact of treatment ...

Phase N/A

5.15 miles

Learn More »

Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers

Reducing the time between the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) is essential to improve the vital prognosis and quality of life of patients. Recent data suggest that some sociocognitive and emotional determinants may explain patient delay from a complementary ...

Phase N/A

5.36 miles

Learn More »

Treatment of Mycobacterium Xenopi Pulmonary Infection

In France, Mycobacterium xenopi is the second non-tuberculous mycobacteria responsible of pulmonary infections. There are few data in the literature regarding its treatment apart from two small randomized trials (42 and 34 patients, respectively) and a French retrospective study (136 patients). So, we decided to conduct a prospective randomized multicenter ...

Phase

5.36 miles

Learn More »

Mucormycosis in ICU

Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. The incidence of Mucormycosis is currently increasing reaching 7% of invasive fungal infections in some immunocompromised patients. Because of its aggressive nature, Mucormycosis is associated with ...

Phase N/A

5.36 miles

Learn More »